Skip to main content

Motion Sickness

1
Pipeline Programs
3
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
Reformulated scopolamine patchPhase 1
Vanda Pharmaceuticals
Vanda PharmaceuticalsWASHINGTON, DC
4 programs
TradipitantPHASE_21 trial
TradipitantPHASE_31 trial
TradipitantPHASE_31 trial
TradipitantPHASE_31 trial
Active Trials
NCT03772340Completed126Est. Jun 2019
NCT05903924Completed316Est. Apr 2024
NCT06138613Active Not Recruiting705Est. Dec 2027
+1 more trials
GSK
GSKLONDON, United Kingdom
1 program
Reformulated scopolamine patchPHASE_11 trial
Active Trials
NCT02839135Completed128Est. Aug 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Vanda PharmaceuticalsTradipitant
Vanda PharmaceuticalsTradipitant
Vanda PharmaceuticalsTradipitant
Vanda PharmaceuticalsTradipitant
GSKReformulated scopolamine patch

Clinical Trials (5)

Total enrollment: 1,641 patients across 5 trials

NCT05903924Vanda PharmaceuticalsTradipitant

Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

Start: Sep 2023Est. completion: Apr 2024316 patients
Phase 3Completed
NCT06138613Vanda PharmaceuticalsTradipitant

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

Start: Feb 2023Est. completion: Dec 2027705 patients
Phase 3Active Not Recruiting
NCT04327661Vanda PharmaceuticalsTradipitant

Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

Start: Nov 2021Est. completion: Apr 2023366 patients
Phase 3Completed
NCT03772340Vanda PharmaceuticalsTradipitant

Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

Start: Dec 2018Est. completion: Jun 2019126 patients
Phase 2Completed
NCT02839135GSKReformulated scopolamine patch

A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.

Start: May 2016Est. completion: Aug 2016128 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.